RxDoctor Payments Data

Ravi Sarin, MD

Nephrology · Muncie, INNPI 1780652867

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $483 of the $654 with a category attached, or 73.7%. 9 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 44.5% of the total. That places this record below the midpoint for nephrology clinicians in IN, where the typical reported total is $871.

$654in general payments, 2019–2025

Across 30 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$291
  • Amgen$116
  • Ardelyx, Inc.$91
  • AstraZeneca$64
  • Aurinia Pharma U.S., Inc.$37
  • Boehringer Ingelheim$22
  • plus $33 from 3 others
$3,612in research payments, 2019–2025

Across 2 payments — averaging $1806.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$4K

What the payments were for

  • Food & beverage$48374%
  • Education$17226%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$654 in reported general payments places this provider in the 45th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$100,631
Medicare patients
227
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl25$71,339
VelphoroSucroferric Oxyhydroxide26$63,417
KerendiaFinerenone43$32,249
AuryxiaFerric Citrate30$32,076
Sevelamer Carbonate119$15,099
Lanthanum Carbonate22$14,893
JardianceEmpagliflozin15$7,613
Calcium Acetate39$4,073
Clonidine21$1,754
Torsemide114$1,686
Calcitriol77$1,612
Hydralazine Hcl64$1,364
Metoprolol Succinate110$1,264
Tacrolimus15$827
Chlorthalidone64$732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$16$63,41726 claims
Boehringer IngelheimJardiance$22$7,61315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 238 nephrology providers in Indiana.

Other nephrology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →